ATNM Submits CMC Meeting Request To FDA For Iomab-B; NBIX Announces Oral Presentation Of NBI-77860 Clinical Trial Data

ATNM announced that it has submitted a request for a CMC meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug. NBIX announced the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860.